A Study to Assess Efficacy and Safety of Baxdrostat in Participants with Primary Aldosteronism

Trial Identifier: D6974C00001
Sponsor: AstraZeneca
Start Date: August 2025
Primary Completion Date: February 2028
Study Completion Date: February 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, Alberta Calgary, Alberta, CA, T2T 5C7
CA, ON Toronto, ON, CA, M4G 3E8
CA, Ontario Ottawa, Ontario, CA, K1H 7W9
CA, QC Montreal, QC, CA, H4J 1C5
DE Berlin, DE, 12203
DE Düsseldorf, DE, 40225
DE Kaiserslautern, DE, 67655
DE München, DE, 80336
DE Reinfeld (Holstein), DE, 23858
DE Würzburg, DE, 97080
ES Barcelona, ES, 08036
ES Madrid, ES, 28046
ES Madrid, ES, 28040
ES Madrid, ES, 28034
ES Sevilla, ES, 41013
GB Cambridge, GB, CB2 0QQ
IT Bologna, IT, 40138
IT Brescia, IT, 25123
IT Firenze, IT, 50134
IT Milano, IT, 20149
IT Milano, IT, 20162
IT Torino, IT, 10126